Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bms-919373 + rosuvastatin
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**BMS-919373 + rosuvastatin** is a combination of two small molecule drugs: BMS-919373, an investigational selective voltage-gated potassium channel Kv1.5 (IKur) blocker, and rosuvastatin, a marketed HMG-CoA reductase inhibitor (statin). BMS-919373 was developed by Bristol Myers Squibb with the primary indication of reducing atrial fibrillation burden by selectively inhibiting Kv1.5, thus affecting cardiac electrical activity. Rosuvastatin lowers cholesterol by inhibiting HMG-CoA reductase and is widely indicated for hyperlipidemia and cardiovascular risk reduction. This specific combination has been studied in clinical trials to evaluate drug-drug interactions, specifically assessing how BMS-919373 affects the pharmacokinetics of rosuvastatin in healthy subjects. BMS-919373’s development was discontinued after Phase 2 trials for atrial fibrillation; rosuvastatin remains approved and marketed worldwide for lipid management and prevention of cardiovascular disease[1][3][4][5][6].
- Other names
- rosuvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)KCNA5 (Ultra-rapid delayed rectifier potassium channel)
Beyond the preview
Go deeper on bms-919373 + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bms-919373 + rosuvastatin.